Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments:
1. Contract Development and Manufacturing Organizations (CDMO)
2. Complex Hospital Generics (Critical Care)
3. Consumer Healthcare (OTC)
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries.
The company's journey in the pharmaceutical sector began in 1988 with the acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions and various organic initiatives. In 2010, the Domestic formulations business was sold to Abbott for $3.7 billion, and Diagnostic Services was sold to Super Religare Laboratories (SRL), marking a strategic shift towards specialized pharmaceutical segments.
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle, serving customers through a globally integrated network of facilities in North America, Europe, and Asia. The company operates out of 15 CDMO sites with a major presence in North America (4), Europe (2), and India (9).
The CDMO segment has been strengthened by significant investments. In conjunction with the 2025 SelectUSA Investment Summit, Piramal Pharma commits to a $90M investment plan towards expanding two of the Company's US facilities. Piramal Pharma's Lexington, Kentucky, facility specializes in sterile compounding, liquid filling, and lyophilization for sterile injectable drug products. Piramal Pharma's Riverview, Michigan site has earned a reputation as an industry leader in the development and manufacturing of active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs) over the past 50+ years.
Piramal Critical Care (PCC) is a leading, global player in inhaled anesthetics hospital generics, maintaining a wide presence across the USA, Europe, and more than 100 countries worldwide. This segment focuses on specialized therapeutic areas including inhalation anesthesia, injectable anesthesia, pain management, and intrathecal therapy.
Piramal Consumer Healthcare (PCH) is one of the fastest-growing businesses of Piramal Pharma Limited. It is among the leading players in the Indian self-care space, with established brands like Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri-Activ, among others, in the Indian Consumer Healthcare market.
Sales rose 11.99% to ₹9,151.18 Crore in the year ended March 2025, as against ₹8,171.16 Crore during the previous year ended March 2024. For the full year, net profit rose 411.39% to ₹91.13 Crore in the year ended March 2025, as against ₹17.82 Crore during the previous year ended March 2024.
For the fourth quarter of FY 2024-25, sales rose 7.90% to ₹2,754.07 Crore in the quarter ended March 2025, as against ₹2,552.36 Crore during the previous quarter ended March 2024. Net profit of Piramal Pharma rose 51.58% to ₹153.50 Crore in the quarter ended March 2025, as against ₹101.27 Crore during the previous quarter ended March 2024.
Piramal Pharma has a Market Capitalization of ₹27,071 Crore (up 28.9% in 1 year), a Revenue of ₹9,151 Crore, and a Profit of ₹91.1 Crore as of recent market data. The company maintains a strong market position with Promoter Holding: 35.0%, providing a stable governance structure.
Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635) offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. The company has established a robust operational framework with strong regulatory compliance.
In FY 2024, PPL successfully completed 341 regulatory inspections, including 44 by the U.S. FDA, with no critical observations. Additionally, close to 1,746 customer audits were conducted across global operations.
The company has committed substantial capital for expansion. These expansions are in response to ongoing demand from US customers, in support of the trend towards US onshoring of drug supply, and in line with Piramal Pharma's overall belief in the value and benefits of US-based innovation. In both cases, Piramal Pharma is making brownfield expansions to existing sites, financed by bank loans and internal accruals, which is the fastest, lowest risk, and most economical way to add new capacities to the US market.
Piramal Pharma operates under three business verticals:
* Piramal Pharma Solutions (PPS): An integrated CDMO having a product suite in niche areas such as highly potent Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), antibody-drug conjugates, potent sterile injectables, hormonal oral solid dosage forms, biologics, and vaccines.
* Piramal Critical Care (PCC): A complex hospital generics (CHG) business in the areas of inhalation anesthesia, injectable anesthesia, pain management, intrathecal therapy, and other injectables.
* India Consumer Healthcare (ICH): A business selling well-known OTC brands.
Apart from this, the Company offers differentiated capabilities in niche areas such as highly potent APIs, antibody-drug conjugates, potent sterile injectables, hormonal oral solid dosage forms, and biologics and vaccines.
Piramal Pharma is distinguished by its engagement in contract development and manufacturing, critical care, and the development of complex hospital generics. The company's approach to leveraging strategic partnerships and focusing on niche markets has established its reputation within the pharmaceutical industry. In 2024, Piramal Pharma reported significant growth, with revenues reaching ₹3,443.22 Crore, emphasizing its successful expansion and innovative contributions to healthcare solutions.
The report highlights Piramal Pharma's approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence. These pillars underscore the company's focus on climate action, supply chain responsibility, innovation, and operational excellence, all while ensuring the well-being of its employees and the communities it serves.
PPL has made substantial progress in its energy efficiency efforts, with a 29% increase in renewable energy consumption.
Piramal Pharma is part of various stock market indices, reflecting its significance in the Indian equity market, including:
* BSE 500, BSE Healthcare, Nifty 500, BSE SmallCap, Nifty Smallcap 100, Nifty Alpha 50, BSE Allcap, BSE SmallCap Select Index, BSE 250 SmallCap Index, BSE 400 MidSmallCap Index, Nifty MidSmallcap 400, Nifty Smallcap 50, Nifty Smallcap 250, Nifty 500 Multicap 50:25:25, Nifty Total Market, Nifty MidSmall Healthcare, Nifty500 Multicap India Manufacturing 50:30:20, Nifty500 Momentum 50, Nifty500 Equal Weight, Nifty500 LargeMidSmall Equal-Cap Weighted.
Piramal Pharma continues to strengthen its position as a leading global pharmaceutical company through strategic investments, operational excellence, and commitment to sustainable growth across its diversified business segments.
